Manhattan Hematology Oncology (MHO) Research Foundation, Inc.

New York, New York 10016

0 studies enrolling now · 1 studies all time

What they study most

CRC, KRAS/NRAS Mutation, Metastatic Colorectal Cancer

Studies at this site

• Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation — Running, not enrolling